Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...